<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515680</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670AIT16T</org_study_id>
    <nct_id>NCT04515680</nct_id>
  </id_info>
  <brief_title>Endocrine Function During Deferasirox Therapy</brief_title>
  <official_title>National Survey on Endocrine Function and Bone Metabolism in Transfusion--dependent Patients Treated With Deferasirox</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A national survey on the prevalence and natural history of endocrine complications in&#xD;
      thalassemia transfusion--dependent patients treated with deferasirox was designed, in order&#xD;
      to assess a larger population during a longer follow up and improve the quality of previous&#xD;
      investigations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2016</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline number of endocrine disorders at study completion</measure>
    <time_frame>baseline through study completion, a minimum of 5 years</time_frame>
    <description>Absolute change in number of patients diagnosed with any endocrine disorder at the baseline and at the study completion</description>
  </primary_outcome>
  <enrollment type="Actual">426</enrollment>
  <condition>Iron Overload</condition>
  <condition>Transfusion-dependent Thalassemia</condition>
  <condition>Endocrine; Complications</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients visited at the participating sites since September 2009 were&#xD;
        recruited into the cohort provided the inclusion criteria were met: affected by TDT and on&#xD;
        deferasirox monotherapy during the study period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult and pediatric patients with transfusion---dependent thalassemia;&#xD;
&#xD;
          -  Chelation with deferasirox as assigned chelation therapy;&#xD;
&#xD;
          -  Available medical history including relevant clinical data (age at start of&#xD;
             transfusion regimen, age at start of chelation therapy, prior chelation therapy,&#xD;
             concomitant diseases and concomitant treatments, including hormonal replacement&#xD;
             treatments if appropriate) and laboratory data (e.g TSH, FT3 and FT4, fasting serum&#xD;
             glucose, OGTT serum glucose, bone mineral density z---score, T---score, g/cm2, PTH,&#xD;
             FSH, LH, testosterone and estradiol, serum ferritin, liver function tests,renal&#xD;
             function tests, MRI T2* value) at baseline and at the end of study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non transfusion- dependent patients;&#xD;
&#xD;
          -  Other chelation therapy than deferasirox or combination with other chelators during&#xD;
             the observation;&#xD;
&#xD;
          -  Absence of complete medical history as above specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universit√† degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>August 13, 2020</last_update_submitted>
  <last_update_submitted_qc>August 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Silverio Perrotta</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

